WNK2 and neoplasm: As with any other biomarker, interpreting the effect of its levels is complex because it is contingent on specific molecular pathways (e.g., the mitogen-activated protein kinase pathway) and presumably depends on circumstances such as tumor burden, tumor response to chemotherapy, or antagonistic or paradoxical effects (Halabian et al., 2009; Kim et al., 2020; Mahajan et al., 2022).